Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2024-11-04 DOI:10.1111/irv.70039

Win Khaing, Chia Jie Tan, Chanthawat Patikorn, Chonnamet Techasaensiri, Oraluck Pattanaprateep, Teerapon Dhippayom, Jackrapong Bruminhent, Nathorn Chaiyakunapruk

{"title":"Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis","authors":"Win Khaing, Chia Jie Tan, Chanthawat Patikorn, Chonnamet Techasaensiri, Oraluck Pattanaprateep, Teerapon Dhippayom, Jackrapong Bruminhent, Nathorn Chaiyakunapruk","doi":"10.1111/irv.70039","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections worldwide, including Thailand. This study aimed to assess clinical and economic burdens of RSV infections across different age groups in Thailand.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A retrospective cohort study was conducted using data from a tertiary care hospital from 2014 to 2021. Patients who tested at least one positive RSV were included and stratified into five age groups (< 2, 2–5, 5–18, 18–65, and > 65 years). Healthcare resource utilization, direct medical costs, and clinical outcomes were analyzed with descriptive statistics. Generalized linear models with gamma distributions and log link were used to model cost outcomes. Costs were reported in 2021 US dollars (USD), with 1 USD = 31.98 Thai Baht.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 2122 RSV-positive patients were identified, half of which (1097) were hospitalized. The median (interquartile range [IQR]) total hospitalization costs ranged from USD780 (IQR: USD488–USD1185) in those < 2 years to USD2231 (IQR: USD1250–USD4989) in those aged 65+ years. Case fatality rates among hospitalized patients also varied from 2.5% to 28.4% depending on age. Increased age, presence of comorbidities, and need for critical care were associated with higher hospitalization costs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Among RSV-positive patients, younger children experienced the greatest burden, but poorer outcomes were observed in older adults. Higher costs were associated with older age, comorbidities and critical care needs. Understanding RSV economic burdens is crucial for assessing the cost-effectiveness and public health value of vaccination programs that prioritize at-risk groups to mitigate the public health impact.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70039","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70039","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections worldwide, including Thailand. This study aimed to assess clinical and economic burdens of RSV infections across different age groups in Thailand.

Method

A retrospective cohort study was conducted using data from a tertiary care hospital from 2014 to 2021. Patients who tested at least one positive RSV were included and stratified into five age groups (< 2, 2–5, 5–18, 18–65, and > 65 years). Healthcare resource utilization, direct medical costs, and clinical outcomes were analyzed with descriptive statistics. Generalized linear models with gamma distributions and log link were used to model cost outcomes. Costs were reported in 2021 US dollars (USD), with 1 USD = 31.98 Thai Baht.

Results

A total of 2122 RSV-positive patients were identified, half of which (1097) were hospitalized. The median (interquartile range [IQR]) total hospitalization costs ranged from USD780 (IQR: USD488–USD1185) in those < 2 years to USD2231 (IQR: USD1250–USD4989) in those aged 65+ years. Case fatality rates among hospitalized patients also varied from 2.5% to 28.4% depending on age. Increased age, presence of comorbidities, and need for critical care were associated with higher hospitalization costs.

Conclusion

Among RSV-positive patients, younger children experienced the greatest burden, but poorer outcomes were observed in older adults. Higher costs were associated with older age, comorbidities and critical care needs. Understanding RSV economic burdens is crucial for assessing the cost-effectiveness and public health value of vaccination programs that prioritize at-risk groups to mitigate the public health impact.

查看原文本刊更多论文

泰国不同年龄段呼吸道合胞病毒感染患者经济和临床疗效的真实世界评估：回顾性队列分析

背景：呼吸道合胞病毒（RSV）是包括泰国在内的全球急性下呼吸道感染的重要病因。本研究旨在评估泰国不同年龄段人群感染 RSV 的临床和经济负担：一项回顾性队列研究使用了一家三级医院 2014 年至 2021 年的数据。研究纳入了至少一次 RSV 检测呈阳性的患者，并将其分为五个年龄组（65 岁）。通过描述性统计对医疗资源利用率、直接医疗成本和临床结果进行了分析。采用伽马分布和对数链接的广义线性模型对成本结果进行建模。成本以 2021 美元（USD）为单位，1 美元 = 31.98 泰铢：共发现 2122 名 RSV 阳性患者，其中一半（1097 人）住院治疗。住院总费用的中位数（四分位数间距 [IQR]）为 780 美元（IQR：488-1185 美元）：在 RSV 阳性患者中，年龄较小的儿童承受的负担最重，但老年人的治疗效果较差。较高的成本与年龄、合并症和重症护理需求有关。了解 RSV 的经济负担对于评估疫苗接种计划的成本效益和公共卫生价值至关重要，疫苗接种计划应优先考虑高危人群，以减轻对公共卫生的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.